Wednesday, May 08, 2024 9:12:21 AM
Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the presentation of new preclinical data demonstrating durable and tunable bidirectional regulation of gene expression in cellular models at the pre-transcriptional level at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, taking place in Baltimore, Maryland, May 7 – 11.
“These exciting new data underscore the versatile capabilities and power of our OMEGA platform,” said Thomas McCauley, Ph.D., Chief Scientific Officer of Omega Therapeutics. “We have demonstrated preclinically that we can prospectively engineer epigenomic controllers to predictably and durably upregulate gene expression across a diverse range of gene types, including turning on inactivated genes, augmenting the expression of genes with low baseline expression levels, and leveraging existing genomic regulatory processes to boost expression. These capabilities unlock a wide spectrum of possibilities to apply precision epigenomic control as a novel therapeutic modality to meaningfully address key drivers of many diseases.”
Recent OMGA News
- Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2024 11:06:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 11:04:21 AM
- Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 05/06/2024 11:00:02 AM
- Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting • GlobeNewswire Inc. • 04/23/2024 11:00:02 AM
- Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control • GlobeNewswire Inc. • 04/09/2024 11:00:31 AM
- Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update • GlobeNewswire Inc. • 03/28/2024 01:15:05 PM
- Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024 • GlobeNewswire Inc. • 03/06/2024 12:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 10:14:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 10:00:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:59:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:00:18 PM
- Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/02/2024 09:05:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:00:09 PM
- Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference • GlobeNewswire Inc. • 12/04/2023 09:00:22 PM
- Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders • PR Newswire (US) • 11/28/2023 12:01:00 AM
- Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics • PR Newswire (US) • 11/21/2023 11:00:00 AM
- Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference • GlobeNewswire Inc. • 11/20/2023 09:00:00 PM
- Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis • GlobeNewswire Inc. • 11/13/2023 12:00:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 12:03:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 12:03:00 PM
- Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 11/09/2023 12:00:17 PM
- Omega Therapeutics to Participate in The Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/07/2023 09:00:20 PM
- Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller • GlobeNewswire Inc. • 10/31/2023 11:00:16 AM
- Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC • GlobeNewswire Inc. • 10/16/2023 11:00:46 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM